Amyotrophic lateral sclerosis: Clinical management and research update

被引:26
作者
Andrews, Jinsy [1 ]
机构
[1] Neurol Inst New York, New York, NY 10032 USA
基金
美国国家卫生研究院;
关键词
QUALITY-OF-LIFE; NONINVASIVE VENTILATION; SURVIVAL; PROGRESSION; DISEASE; TRIAL; CARE; ALS; PREVALENCE; IMPROVES;
D O I
10.1007/s11910-009-0010-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that selectively affects the motor neurons of the brain and spinal cord. ALS occurs in about 1 in 100,000 individuals. Although recent advances have been made in understanding the pathogenesis of ALS, there has been no new effective pharmacotherapy since the approval of riluzole more than 10 years ago. The mainstay of clinical management includes pharmacologic management of symptoms, management of dysphagia and respiratory symptoms, palliative care, and multidisciplinary care clinics. In this review, we discuss the clinical management of ALS, recent modifications to the diagnostic criteria, and current clinical trials.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 48 条
[1]
Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence-based review with good practice points. EALSC Working Group [J].
Andersen, Peter Munch ;
Borasio, Gian Domenico ;
Dengler, Reinhard ;
Hardiman, Orla ;
Kollewe, Katja ;
Leigh, Peter Nigel ;
Pradat, Pierre-Francois ;
Silani, Vincenzo ;
Tomik, Barbara .
AMYOTROPHIC LATERAL SCLEROSIS, 2007, 8 (04) :195-213
[2]
Emerging disease-modifying therapies for the treatment of motor neuron diseasd/amyotropic lateral sclerosis [J].
Bedlack, Richard S. ;
Traynor, Bryan J. ;
Cudkowicz, Merit E. .
EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (02) :229-252
[3]
A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BENSIMON, G ;
LACOMBLEZ, L ;
MEININGER, V ;
BOUCHE, P ;
DELWAIDE, C ;
COURATIER, P ;
BLIN, O ;
VIADER, F ;
PEYROSTPAUL, H ;
DAVID, J ;
MALOTEAUX, JM ;
HUGON, J ;
LATERRE, EC ;
RASCOL, A ;
CLANET, M ;
VALLAT, JM ;
DUMAS, A ;
SERRATRICE, G ;
LECHEVALLIER, B ;
PEUCH, AJ ;
NGUYEN, T ;
SHU, C ;
BASTIEN, P ;
PAPILLON, C ;
DURRLEMAN, S ;
LOUVEL, E ;
GUILLET, P ;
LEDOUX, L ;
ORVOENFRIJA, E ;
DIB, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591
[4]
Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis [J].
Bourke, SC ;
Tomlinson, M ;
Williams, TL ;
Bullock, RE ;
Shaw, PJ ;
Gibson, GJ .
LANCET NEUROLOGY, 2006, 5 (02) :140-147
[6]
Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities [J].
Chiò, A. ;
Bottacchi, E. ;
Buffa, C. ;
Mutani, R. ;
Mora, G. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (08) :948-950
[7]
TRANSPLANTS OF EMBRYONIC MOTONEURONS TO ADULT SPINAL-CORD - SURVIVAL AND INNERVATION ABILITIES [J].
CLOWRY, G ;
SIERADZAN, K ;
VRBOVA, G .
TRENDS IN NEUROSCIENCES, 1991, 14 (08) :355-357
[8]
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis [J].
Cudkowicz, Merit E. ;
Shefner, Jeremy M. ;
Simpson, Elizabeth ;
Grasso, Daniela ;
Yu, Hong ;
Zhang, Hui ;
Shui, Amy ;
Schoenfeld, David ;
Brown, Robert H. ;
Wieland, Scott ;
Barber, Jack R. .
MUSCLE & NERVE, 2008, 38 (01) :837-844
[9]
Cudkowicz ME, 2007, NEUROLOGY, V68, pA90
[10]
Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population [J].
Czaplinski, A ;
Yen, AA ;
Appel, SH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (03) :390-392